Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-2 of 2
Keywords: Tremelimumab
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka
Journal:
Oncology
Oncology 1–6.
Published Online: 11 November 2024
...Yasutoshi Fujii; Tomokazu Kawaoka; Yuki Shirane; Ryoichi Miura; Hikaru Nakahara; Kenji Yamaoka; Shinsuke Uchikawa; Hatsue Fujino; Atsushi Ono; Eisuke Murakami; Daiki Miki; Nelson Clair Hayes; Masataka Tsuge; Yuko Nakamura; Kazuo Awai; Shiro Oka Introduction: Durvalumab plus tremelimumab combination...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (2017) 93 (Suppl. 1): 147–159.
Published Online: 20 December 2017
... carcinoma (HCC). Results of combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab in HCC were presented at the 2017 annual meeting of the ASCO (American Society of Clinical Oncology). Response rates were 25% in all 40 patients and 40% in the 20 uninfected...